Tata Elxsi, a leader in design and technology services, has announced the inauguration of the ‘Terumo–Tata Elxsi Offshore Development Center’. This new centre aims to bolster Terumo Corporation‘s cardiac and vascular solutions by enhancing engineering and innovation capabilities, providing continuous lifecycle support across international markets.
The centre combines multidisciplinary teams with Tata Elxsi’s expertise in design, engineering, verification, regulatory compliance, and localisation. By integrating AI, GenAI, and digital capabilities in software engineering, the centre facilitates faster development and regional adaptation, addressing the increasing demand for patient-centric medical devices with improved cost efficiency and product differentiation.
The collaboration is set to enhance the reliability and performance of cardiac and vascular technologies, ensuring their global availability and compliance with industry standards while meeting the evolving needs of healthcare providers and patients.
Fumihisa Hirose, Company President of Terumo Corporation’s Cardiac & Vascular Company, commented, “This new Offshore Development Center strengthens our ability to innovate faster and deliver high-quality medical technologies across global markets. Tata Elxsi’s integrated design, engineering, and regulatory expertise will help us accelerate our global product roadmap while maintaining the highest standards of safety and compliance.”
Sreevatsa Sahasranaman, Senior Vice President & Head of Healthcare & Life Sciences at Tata Elxsi, stated, “This Offshore Development Center represents a comprehensive long-term partnership model with Terumo Corporation to bring Tata Elxsi’s multi-disciplinary, cross-functional and deep domain expertise to drive innovation and cost efficiencies across Terumo’s Cardiovascular portfolio. We are committed to combining design, engineering, and regulatory capabilities, enhanced by the latest AI- and GenAI-powered technologies, to help Terumo bring next-gen medical technologies to global and emerging markets.”
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).